Update (June 23): The RECOVERY group posted the results of its study on dexamethasone to medRxiv on June 22. In a press release on Tuesday (June 16), researchers from a large, randomized controlled ...

Paris, February 25, 2025. The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of ...

Objective: To compare the efficacy and tolerability of dexamethasone-21-palmitate and mepivacaine alone and in combination in the acute treatment of facet syndrome. Results: In all three groups ...

The glucocorticoid dexamethasone (Dex) is widely used in preterm infants for the prevention of chronic lung disease. However, major concern has arisen about the long-term sequelae of this therapy.

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan.

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

The primary corticosteroid used to control cerebral edema is dexamethasone. More than 40 years ago, dexamethasone was used in patients with brain tumors, and it is still used today. Other steroids ...

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus ...

Dexamethasone phosphate (as sodium); 4mg/mL, 10mg/mL; soln for IV or IM inj; contains sulfites. Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens.

FRIDAY, Jan. 24, 2025 (HealthDay News) -- For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival ...